$536 Million is the total value of MPM ASSET MANAGEMENT LLC's 8 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RPTX | Repare Therapeutics, Inc. | $92,426,000 | -0.8% | 3,003,772 | 0.0% | 17.24% | -37.8% | |
| TCRR | TCR2 Therapeutics, Inc. | $82,314,000 | +32.3% | 4,050,865 | 0.0% | 15.35% | -17.1% | |
| HARP | Harpoon Therapeutics, Inc. | $76,870,000 | +2.4% | 4,524,425 | 0.0% | 14.33% | -35.9% | |
| RYTM | Rhythm Pharmaceuticals, Inc. | $41,374,000 | -2.8% | 1,909,258 | 0.0% | 7.72% | -39.1% | |
| CHMA | Chiasma, Inc. | $24,666,000 | -20.1% | 5,736,296 | 0.0% | 4.60% | -49.9% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-13
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| Chiasma, Inc. | 24 | Q2 2021 | 19.8% |
| Aratana Therapeutics, Inc. | 24 | Q1 2019 | 26.8% |
| Conatus Pharmaceuticals, Inc. | 23 | Q1 2019 | 9.7% |
| Rhythm Pharmaceuticals, Inc. | 19 | Q2 2022 | 69.9% |
| Harpoon Therapeutics, Inc. | 19 | Q3 2023 | 31.9% |
| Syndax Pharmaceuticals, Inc. | 19 | Q3 2020 | 14.5% |
| Radius Health, Inc. | 17 | Q2 2018 | 76.4% |
| TCR2 Therapeutics, Inc. | 17 | Q1 2023 | 29.1% |
| Proteon Therapeutics, Inc. | 17 | Q4 2018 | 3.0% |
| EpiZyme, Inc. | 15 | Q4 2016 | 35.9% |
View MPM ASSET MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-13 |
| 13F-HR | 2023-11-14 |
| 13F-HR/A | 2023-09-07 |
| 13F-HR | 2023-08-14 |
| 4 | 2023-06-05 |
| 4 | 2023-05-24 |
| 13F-HR | 2023-05-12 |
| 13F-HR | 2023-02-14 |
| 13F-HR | 2022-11-14 |
View MPM ASSET MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.